CLINICAL USE

Antiviral: Herpes zoster and simplex Prevention of cytomegalovirus (CMV) disease after renal transplantation

DOSE IN NORMAL RENAL FUNCTION

Herpes simplex: 500 mg twice daily for 5–10 days Herpes zoster: 1 g 3 times a day for 7 days Herpes simplex suppression: 500 mg daily in 1–2 divided doses (500 mg twice daily in the immunocompromised) Prevention of CMV disease: 1 g 3 times a day for 90 days

PHARMACOKINETICS

  • Molecular weight                           : 360.8 (as hydrochloride)
  • %Protein binding                           : 15
  • %Excreted unchanged in urine     : <1
  • Volume of distribution (L/kg)       : 0.7
  • half-life – normal/ESRD (hrs)      : 3/14

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

    30–50 Dose as in normal renal function 15–30 Herpes simplex: Dose as in normal renal function Herpes zoster: 1 g every 12 hours CMV prophylaxis: 1 g every 12 hours <15 Herpes simplex: 500 mg daily Herpes zoster: 1 g every 24 hours CMV prophylaxis: 1 g every 24 hours Herpes simplex suppression: Immunocompetent – 250 mg daily Immunocompromised – 500 mg daily

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                : Likely dialysability. Dose as in GFR<15 mL/min
  • HD                     : Dialysed. Dose as in GFR<15 mL/min post dialysis
  • HDF/high flux   : Dialysed. Dose as in GFR<15 mL/min post dialysis
  • CAV/VVHD      : Likely dialysability. Dose as in GFR=15–30 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • Ciclosporin: may alter ciclosporin levels Mycophenolate: higher concentrations of both aciclovir and mycophenolic acid on concomitant administration

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments

    OTHER INFORMATION

    Almost completely (80%) converted to aciclovir – see aciclovir monograph for further information

  • Bioavailability of aciclovir from 1 g oral dose of valaciclovir is 54% Mean peak aciclovir concentrations occur 1.5 hours post dose; peak plasma concentrations of valaciclovir are 4% of aciclovir levels, occur at a median of 30–60 minutes post dose, and are at or below the limit of quantification 3 hours post dose The dose quoted in the literature for CMV prophylaxis in transplant recipients is 2 g 4 times a day. However, in practice this results in severe aciclovir toxicity, especially in patients with poorly functioning grafts .
  • Related News